| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President & CEO | Interim CEO
2 companies
Anthony G. Quinn last filed a Form 4 in June 2025, as President & CEO at SYRE. The filings on record cover 2 companies. Anthony G. Quinn's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Anthony G. Quinn a below-average insider score of 37/100, based on 9 past trades. Over a 12-month horizon, 11.1% of those trades were profitable, with an average 12-month return of -64.5%.
At the last filing, the largest reported position was 550,540 shares of SYRE. Net of sales, the SYRE filings show accumulation of 558,992 shares.
Anthony G. Quinn has 34 Form 4 filings on record from April 2016 to June 2025, across 2 companies: Director at Generation Bio (GBIO), 2020–2025; President & CEO at Spyre Therapeutics (SYRE), 2016–2022.
The 60 reported transactions were 29 open-market purchases, 17 option or other derivative awards, 11 option exercises and 2 gifts, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 13 purchases worth about $2.5M and no sales.
The largest open-market purchase was 165,000 shares of SYRE at an average $4.75 on April 30, 2020, about $784K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 13, 2025 | GBIO Generation Bio Co. | Director | Buy | 210,791 | $0.96 | $203,209.36 | +238.2% | -59.3% | -38.8% | |
| Dec 1, 2023 | GBIO Generation Bio Co. | Director | Buy | 88,495 | $1.41 | $124,777.95 | New | +80.6% | +9.4% | |
| Mar 16, 2022 | SYRE Spyre Therapeutics, Inc. | President & CEO | Buy | 80,079 | $2.34 | $187,705.18 | +17.0% | -71.1% | -85.9% | |
| Mar 15, 2022 | SYRE Spyre Therapeutics, Inc. | President & CEO | Buy | 144,666 | $1.94 | $280,942.97 | +44.0% | -60.5% | -83.4% | |
| Dec 10, 2021 | SYRE Spyre Therapeutics, Inc. | President & CEO | Buy | 53,634 | $3.71 | $198,972.10 | +19.5% | -43.0% | -89.9% | |
| Apr 30, 2020 | SYRE Spyre Therapeutics, Inc. | President & CEO | Buy | 165,000 | $4.75 | $783,750.00 | +44.2% | - | - | |
| Jun 14, 2019 | SYRE Spyre Therapeutics, Inc. | President & CEO | Buy | 31,905 | $6.16 | $196,453.22 | +9.9% | - | - | |
| May 22, 2019 | SYRE Spyre Therapeutics, Inc. | President & CEO | Buy | 26,592 | $6.77 | $180,032.46 | +9.0% | - | - | |
| May 17, 2019 | SYRE Spyre Therapeutics, Inc. | President & CEO | Buy | 18,713 | $6.75 | $126,398.71 | +6.8% | - | - | |
| Aug 15, 2018 | SYRE Spyre Therapeutics, Inc. | President & CEO | Buy | 2,994 | $7.05 | $21,115.22 | +3.2% | - | - |